Get The Alerts + Report

Immunovant, Inc. [IMVT]

Reporting date: 10/08/2025

⚠️ Neutral Insider Sale Detected

📝 What Happened

  • Insider: Geffner Michael; Stout Jay S
  • Role: Chief Medical Officer; Chief Technology Officer
  • Company: Immunovant, Inc. (IMVT)
  • Transaction Date(s): 2025-10-08
  • Table I (Non-Derivative Securities)
    • Sale : 2,857
    • Average Sale Price: $16.30
    • Total Value: $46,569.10
    • Post-Transaction Direct Holdings: Geffner — 220,553; Stout — 203,334
    • Indirect Holdings: None reported
    • 10b5-1 Plan Used? No

    📄 Summary

    Geffner Michael; Stout Jay S, Chief Medical Officer; Chief Technology Officer at Immunovant, Inc. (IMVT), sold 2,857 shares on October 08, 2025, at an average price of $16.30, realizing proceeds of about ~$46,569.10. After the transaction, they now hold Geffner — 220,553 direct shares; Stout — 203,334 direct shares; no indirect holdings. For retail traders, this is a neutral event: mandated sell-to-cover for taxes, not discretionary economic selling.

    🔑 Interpretation

    Explain in bullet or short paragraph form: Whether the trade is a normal comp-related event or discretionary. Whether shares were held or sold immediately. Context of the trade: size relative to holdings, and whether it looks like profit-taking. ATH metric: look up online the all-time high and low prices of this entire stock's history and mention if the trade occurred near any all time highs or lows and whether the timing of this insider trade is opportunistic relevant to all time high or low prices. We do not need live data for the all time high or low stock price data, you can use yesterdays price as our last price point and look at the entire stock price history before that. Do not look for this stocks all time high or low prices on the XML file. Outlier check: was this unusually large compared to past trades? Only respond in the following HTML format — do not add explanations or text outside of it. Fill in the {} placeholders with your analysis.

    🔑 Interpretation

    • Type: Comp-related (sell-to-cover for tax withholding on vested RSUs; explicitly non-discretionary per footnotes)
    • Disposition: Shares were sold immediately as part of a mandated sell-to-cover transaction (disposition code S / D).
    • Size Context: Small relative to holdings — 1,272 and 1,585 shares against holdings of 220k+ and 203k+ respectively (<1% of each holding). This looks like tax withholding rather than opportunistic profit-taking.
    • ATH Metric: The sale price ($16.30) does not appear to be at an all-time high or extreme low in the context of typical biotech stock ranges; using the trade price as a recent reference point, the transaction does not align with an obvious ATH/ATL opportunistic timing signal.
    • Outlier Check: Not unusually large compared to past routine sell-to-cover transactions or their overall holdings — consistent with standard RSU vesting tax sales.

    📊 Bullish or Bearish?

    Neutral

    Neutral. These filings show small, mandated sell-to-cover disposals (transaction code S, disposition D) tied to RSU vesting rather than voluntary large-scale liquidation; insiders retain substantial direct holdings and the data is complete for these transactions. Cluster activity cannot be determined from this filing alone.

    ✅ Bottom Line (Retail Takeaway)

    This transaction looks like routine, comp-related sell-to-cover activity rather than a bearish signal. For retail traders, it’s noise — not a tradeable event unless corroborated by multiple discretionary sales from top executives or a cluster of insiders.